Reliability and Validity of the PReFS (PReFS)

Reliability and Validity of the Pressure Relief Frequency Scale

This study is testing the psychometric properties of a new tool to determine recommendations for pressure relief frequency in wheelchair users.

Study Overview

• Status: Recruiting
• Conditions: Stroke; Traumatic Brain Injury; Spinal Cord Injury; Neurologic Disorders
• Intervention / Treatment: Other: Interview

Detailed Description

The goal of the proposed study is to establish the content validity and inter-rater reliability of a new tool, the Pressure Relief Frequency Scale (PReFS). Findings from this study will provide clinicians with a tool that can be used to develop an individualized approach to teaching patients how frequently to perform weight shifts. The part of the study will establish the inter-rater reliability of the PReFs through video recordings of individuals who are wheelchair users.

• Study Type: Observational
• Enrollment (Estimated): 15

Contacts and Locations

• Study Contact: Name: Antonia Silva, DPT; Phone Number: 757-831-4354; Email: antonia_silva@baylor.edu
• Study Contact Backup: Name: Elizabeth Ardolino, PT, PhD; Phone Number: 215-605-9319; Email: liz_ardolino@baylor.edu

Study Locations

• United States
  • Texas
    • Waco, Texas, United States, 76798
      • Recruiting
      • Baylor University
      • Contact: Antonia Silva, DPT; Phone Number: 757-831-4354; Email: antonia_silva@baylor.edu
      • Contact: Elizabeth Ardolino, PT, PhD; Phone Number: 215-605-9319; Email: liz_ardolino@baylor.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Individuals with a diagnosed neurologic disorder who are primary wheelchair users.

Description

Inclusion Criteria:

• primary wheelchair user
• diagnosed with a neurologic disorder

Exclusion Criteria:

• does not use a wheelchair for more than 50% of waking hours

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Wheelchair Users; Individuals with a neurologic disorder who are primary wheelchair users	Other: Interview; Participants will be interviewed for this study. No intervention will occur.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Interview	Each participant will take part in a 10-minute interview to answer questions on the PReFS	Baseline

Collaborators and Investigators

• Sponsor: Baylor University
• Investigators: Principal Investigator: Elizabeth Ardolino, PT, PhD, Baylor University

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: December 1, 2025
• First Submitted That Met QC Criteria: December 1, 2025
• First Posted (Estimated): December 12, 2025

Study Record Updates

• Last Update Posted (Actual): December 23, 2025
• Last Update Submitted That Met QC Criteria: December 17, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: pressure relief; wheelchair user; skin integrity
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Wounds and Injuries; Craniocerebral Trauma; Trauma, Nervous System; Spinal Cord Diseases; Brain Injuries; Brain Injuries, Traumatic; Stroke; Spinal Cord Injuries; Nervous System Diseases; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Data Collection; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Interviews as Topic
• Other Study ID Numbers: 2339946

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No